Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
    • IRS Aquiesces in Generic Drug Legal Expense Decisions (AOD 2026-3, AOD 2026-4)
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • IRS Establishes New Correction Program for Individual Retirement Arrangements (Rev. Proc. 2026-33)
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • IRS Updates EPCRS to Reflect SECURE 2.0 Act (Rev. Proc. 2026-34)
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • Partnership’s Conservation Easement Deduction Sharply Reduced; Valuation Penalty Sustained (Lontrac Enterprises, TCM)
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • Taxpayer Received Tax Credits Despite Ineligible Income Level (Blas, CA-9)
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • West Virginia Disaster Notice Updated (WV-2026-01)
      • You have 1 more complimentary views available this month. Log in if you are already a customer
  • Articles
    • Articles

    Federal Tax Day - Current, I.3, IRS Aquiesces in Generic Drug Legal Expense Decisions (AOD 2026-3, AOD 2026-4), (Oct 23, 2026)

    The IRS has acquiesced to two court decisions involving the legal expenses of generic drug manufacturers. The courts found that a Generic’s legal expenses incurred in defending patent infringement suits during the pendency of the approval proc ...

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use